Vaccine myocarditis risk reaches 1 in 10,000 for adolescent boys But while the rate of Pfizer-related myocarditis continues to increase in males aged 12–17, research cited by the TGA indicates the risk is still dwarfed by the threat COVID-19 poses to this cohort.
TGA monitoring overseas Moderna recommendations Several countries have limited the use of the mRNA vaccine in younger people, but there is no sign Australia will institute a similar pause.
Adolescents at most risk of developing myocarditis: TGA Myocarditis rates related to the Pfizer vaccine been released, while the Moderna vaccine has been included in the safety report for the first time.
Five further blood clot cases linked to AstraZeneca The latest TGA safety report also confirms no vaccine-related fatalities have occurred in the past week, in stark contrast to 62 COVID deaths.
No fatalities among seven new AZ blood clots cases The additional cases mean thrombosis with thrombocytopenia syndrome is occurring at a rate of 1.29 per 100,000 doses administered.
Two more AstraZeneca-linked deaths in past week: TGA The latest fatalities mean Australia has now recorded nine deaths linked to the vaccine, compared to more than 1000 COVID deaths.
Guillain-Barre Syndrome warning for AstraZeneca The TGA has updated the vaccine’s Product Information regarding the ‘very rare’ possibility of contracting the disorder.
Eleven blood clot cases linked to AstraZeneca in past week There were no deaths associated with the vaccine, but six thrombosis with thrombocytopenia syndrome cases remain in hospital.
Another death linked to AstraZeneca A 34-year-old woman has died after developing a rare blood-clotting disorder linked to the vaccine, the TGA has announced.
Two more deaths linked to AstraZeneca vaccine There have now been six Australian deaths related to the AstraZeneca vaccine, out of more than 6.1 million administered doses.